Do You Need a Prescription for ARA-290? Is It Legal to Buy Online?

At Pepti, ARA-290 is $219 a month all-in for a 5 mL vial containing 10 mg (2 mg/mL), with physician review, refill management and refrigerated shipping included and no membership fee.

What Category 3 means

The FDA sorts substances nominated for the 503A bulks list into three interim categories. Category 1 is "under evaluation." Category 2 is "raise significant safety risks." Category 3 is "nominated without adequate support": the nomination did not include enough information for the FDA to evaluate the substance. It is a paperwork category. A nominator can resubmit with adequate support, at which point a substance can move to Category 1.

So the accurate description is: not flagged for a safety concern, not yet evaluated for the bulks list because the nomination was incomplete, and not scheduled for committee review. Category 3 is not a ban and not an endorsement. Compounded medications are not FDA approved.

The research-use regulation, 21 CFR 201.125, covers material for research "not involving clinical use." A person injecting it is the clinical use the regulation excludes. A second regulation, 21 CFR 201.128, looks at a seller's objective intent, including advertising, so a site selling "research" ARA-290 alongside neuropathy dosing advice is describing a human use. More is in research peptides vs prescription peptides and can you buy peptides without a prescription.

ARA-290 is specifically named as a prohibited peptide in the anti-doping literature, and detection methods for it have been published. It does not raise red cell counts, so it is not a blood-doping agent, but that does not make it permitted. A prescription does not create an exemption. If you are tested by any sporting body, check the current prohibited list for your sport before starting anything and tell your physician.

A review should also cover what is behind your symptoms. Small-fiber neuropathy has testable causes, such as B12 deficiency, thyroid disease and poorly controlled glucose, and anyone on insulin or other glucose-lowering medication should tell their physician because one ARA-290 trial reported changes in hemoglobin A1c. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

ARA-290 has more human data than most compounded peptides, and it is still limited. Randomized, placebo-controlled phase 2 trials in sarcoidosis-associated small-fiber neuropathy (Molecular Medicine 2012 and 2013, and a 64-person dose-ranging trial in Investigative Ophthalmology and Visual Science in 2017) and in type 2 diabetes with painful neuropathy (Molecular Medicine 2015) reported improved neuropathy symptom questionnaires and increased corneal nerve fiber measures after four weeks. The trials were small, short and run by the developer. Pain-intensity scores did not clearly separate from placebo, and in the 2017 trial only the middle dose beat placebo on the primary endpoint. A 2020 open-label study in diabetic macular edema found no improvement. No phase 3 trial exists. More is in ARA-290 benefits and ARA-290 side effects.

1. Complete the free online assessment: your symptoms, history, medications and allergies.
2. A physician licensed in your state reviews it, usually within 24 hours, and may ask questions or decline if ARA-290 is not the right fit.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it. Lot results are at lab results.
4. It ships refrigerated with ice packs as a ready-to-use multi-dose solution, with sterile syringes, alcohol prep pads and your directions printed on the vial.
5. Refills every 28 days, one vial per fill, with your care team reachable in between.

ARA-290 is a vial and syringe only; there is no pen. Pepti is cash-pay, does not bill insurance, and prescribes in most US states, not currently in Oklahoma. For comparisons, see KPV vs ARA-290 and thymosin alpha-1 vs ARA-290.